Digital PCR Market

Digital PCR is a USD 661.9 million business in 2025, and it reaches USD 1.41 billion by 2035, growing 7.87% a year. Digital PCR covers the instruments that split one sample into thousands of partitions, the consumables and assays that run inside them, and the software and service around them, used to count DNA or RNA copies without a standard curve. Our receipt: 17,640 active systems multiplied by USD 37,520 of annual revenue per system gives the 2025 total. The clearest recent signal came on 7 July 2025, when Bio-Rad announced it had completed the purchase of Stilla Technologies and launched the QX Continuum and QX700 series, putting droplet and Stilla’s Nio platform under one owner. This study is part of the life science instruments research hub, and every figure follows the Douglas Insights research methodology.

How much do labs spend per digital PCR system and per partitioned sample?

Douglas Insights estimates each active digital PCR system earned its vendor USD 37,520 in 2025. Consumables and assays took USD 23,150, new-instrument value spread across the fleet USD 10,280, and software and service USD 4,090. Consumables carry 61.7% of spend, so this is a razor-and-blade business.

Instrument prices fall into three bands on Douglas Insights price checks. Entry plate readers for single labs sell for roughly USD 45,000 to USD 80,000. Mid-throughput systems with five to seven colour channels land between USD 90,000 and USD 160,000. Automated or clinical configurations, including in vitro diagnostic (IVD) registered systems, run above USD 150,000 once software validation is bought. About 2,240 new digital PCR systems were placed in 2025 at a blended USD 81,000, which is the USD 181.4 million instrument line.

Per sample, a research reaction in a nanoplate or droplet cartridge costs USD 4 to USD 12 in consumables and master mix. A clinical kit reaction, sold with a validated assay, fetches USD 25 to USD 60. The 1.0% price leg comes from that mix: clinical kits and automation lift revenue per system faster than cheaper domestic Chinese instruments pull it down. By 2035 revenue per system reaches USD 41,445.

Where does digital PCR stop and quantitative PCR or sequencing take over?

Digital PCR answers one question that quantitative PCR (qPCR) cannot: how many copies are present, counted directly at 0.1% variant frequency or lower. Bio-Rad sizes this absolute quantitation segment at about USD 600 million, against roughly USD 2.7 billion for qPCR and USD 2.4 billion for targeted sequencing.

Those three figures come from the Bio-Rad digital PCR investor presentation of August 2025, and they bracket the boundary of this study. Included: droplet digital PCR, nanoplate and chip-based digital PCR, their consumables and reagents, assay kits, software and services. Excluded: qPCR thermocyclers that run no partitioned workflow, next-generation sequencing (NGS) libraries and lab-developed services billed by reference labs. Our 2024 equivalent of USD 613.6 million sits 2.3% above that Bio-Rad figure, because it adds Chinese domestic vendors and service revenue.

By product the split is clear: consumables and reagents hold 61.7%, instruments 27.4% and software and services 10.9% of 2025 revenue. By end user, academic and government laboratories, biopharma companies and clinical and reference laboratories each buy differently, and the application table below tracks where the money goes.

Which application makes the money in digital PCR, and which grows fastest?

Oncology and liquid biopsy lead with 31.6% of 2025 digital PCR revenue, or USD 209.2 million, because rare-mutation counting in plasma is where partitioning beats qPCR most clearly. Cell and gene therapy and bioprocess QC grows fastest, at 10.8% a year.

Oncology and liquid biopsy earns USD 209.2 million today and USD 490.7 million by 2035, at 8.9% a year, as minimal residual disease (MRD) monitoring adds repeat draws per patient; our Breast Cancer Liquid Biopsy Market report tracks the downstream test volumes. Academic and genomics research takes USD 160.8 million, the second-largest block, but grows only 4.1% because grant budgets are flat. Cell and gene therapy and bioprocess QC is worth USD 150.3 million and climbs to USD 419.1 million: vector genome titre, residual DNA and copy-number release tests need absolute counts, and quality control (QC) labs repeat them on every lot. Infectious disease and wastewater surveillance holds USD 91.3 million, down from its pandemic peak, growing 5.2%. Transplant, prenatal and other clinical testing is the smallest at USD 50.3 million, yet donor-derived cell-free DNA tests keep it at 7.5% a year.

Does droplet or nanoplate partitioning win new digital PCR placements?

Bio-Rad droplet digital PCR readers still make up about 50.5% of active digital PCR systems in 2025 on our count. Nanoplate and chip-based digital PCR took roughly 55% of new placements, because they need fewer hands-on steps and suit qPCR-trained staff.

QIAGEN reported more than 3,200 cumulative QIAcuity nanoplate placements and over 100 additions per quarter through 2025 in its full-year 2025 results of 4 February 2026. Thermo Fisher entered with the QuantStudio Absolute Q in September 2021, a microfluidic array system quoting 90 minutes to result, and Roche launched the Digital LightCycler in 15 countries in August 2022. Bio-Rad answered with the QX Continuum and the seven-colour QX700 series. Droplets still own the fleet. Bio-Rad’s 12,000-plus peer-reviewed droplet publications from 2012 to 2024 remain the strongest lock-in on the droplet side.

Why are cell therapy and liquid biopsy labs adding digital PCR capacity?

Four forces add 6.8 percentage points a year to the active digital PCR fleet, as Douglas Insights calculates. Cell and gene therapy QC adds 2.3, oncology monitoring 2.1, qPCR assay conversion 1.4 and Chinese domestic placements 1.0. Together they lift the fleet from 17,640 systems to 34,057 by 2035.

Cell and gene therapy and bioprocess release testing contributes 2.3 points. Every viral-vector lot needs a genome titre, a residual host-cell DNA count and often a replication-competent virus check, and absolute counting removes the standard curve that regulators question. Bio-Rad lists more than 60 cell and gene therapy assays in its catalogue, and QIAGEN said in February 2026 that it plans cell and gene therapy launches and a Hamilton-built automated nanoplate handler for regulated workflows, as its results release states. Contract manufacturers add systems with each new suite; our Cell and Gene Therapy CDMO Services Market study tracks that build-out.

Oncology monitoring adds 2.1 points. Tumour-informed MRD panels and EGFR, KRAS or PIK3CA hotspot tests in plasma need a variant allele fraction of 0.1% or lower, which digital partitioning reads with fewer replicates than qPCR. A patient on MRD surveillance gives 4 to 8 blood draws a year, so each oncology client adds recurring cartridge demand rather than a one-off purchase. A hospital lab running 2,000 such draws a year at USD 25 to USD 60 per clinical kit reaction buys USD 50,000 to USD 120,000 of consumables, more than the reader itself. Bio-Rad catalogues more than 34,000 mutation detection assays, according to its digital PCR presentation.

Conversion of existing qPCR assays adds 1.4 points. Bio-Rad states its combined catalogue holds more than 490,000 validated assays, including 445,000 gene expression assays that run on qPCR today. Lower running cost per well on the QX Continuum and a qPCR-like workflow on nanoplates mean a core lab can move copy-number and gene-editing assays across without revalidating chemistry. Converting even 2% of those catalogue assays to partitioned runs adds about 8,900 assays to the digital menu.

Chinese domestic placements add 1.0 point. Hospital buyers in China favour locally registered instruments under volume-based procurement, and domestic vendors such as TargetingOne won the first class III registration for a digital PCR kit from the National Medical Products Administration (NMPA). We count about 2,400 active domestic-brand systems in China, which is why Asia Pacific grows fastest.

Which headwinds slow digital PCR instrument purchases?

Three headwinds remove 1.7 points from digital PCR fleet growth in the slower case: academic funding pressure takes 0.9, sequencing-based MRD competition 0.5 and clinical validation cost 0.3. They explain why our base case sits below published forecasts.

Academic funding pressure removes 0.9 points. Bio-Rad’s Life Science segment sold USD 1.02 billion in 2025, down 1.3% on a currency-neutral basis, which the company tied to a constrained academic research and biotech funding environment in its full-year 2025 results. Academic and government laboratories own roughly 41% of active digital PCR systems on our count, so deferred capital orders hit placements first. Academia is the soft spot.

Sequencing-based MRD takes 0.5 points. Tumour-informed NGS panels track 16 to 50 variants per patient, against 1 to 6 for a digital PCR panel, and payers that reimburse one test per draw tend to pick the broader one. Clinical validation cost removes 0.3 points: an IVD-registered digital PCR assay needs a separate analytical and clinical study per indication, often costing USD 1 million to USD 3 million per kit on Douglas Insights benchmarks.

Which companies own the digital PCR installed base after the Stilla deal?

Douglas Insights puts Bio-Rad at 50.8% of 2025 digital PCR revenue after absorbing Stilla, and the top three, with QIAGEN and Thermo Fisher, at 76.4%. Shares are our estimates built from installed systems and consumable pull-through; no vendor discloses digital PCR revenue separately.

Bio-Rad’s position rests on 15 years of droplet chemistry since the QX100 of 2010 and a fleet we put near 9,650 systems including Stilla units. The binding offer for Stilla was announced on 13 February 2025, and the 7 July 2025 completion moved Stilla’s seven-colour Nio users onto the QX700 roadmap. QIAGEN, at 15.9%, sells QIAcuity into labs already buying its extraction kits; its PCR and nucleic acid amplification product group sold USD 231.2 million in the first nine months of 2025, per its third-quarter report, a line that includes QIAcuity alongside qPCR reagents.

Thermo Fisher built its 9.7% share on the Applied Biosystems sales force after buying Combinati, as its September 2021 launch release states. Roche, at 3.6%, sells the Digital LightCycler as a CE-marked, FDA 510(k)-exempt system for clinical labs, according to its launch release of 23 August 2022. Chinese domestic vendors share 11.2%, led by Beijing-based TargetingOne. Smaller rivals fight on price. Sysmex, through its OncoBEAM service, uses digital BEAMing chemistry inside its own oncology tests rather than selling instruments.

Which region buys the most digital PCR, and where is growth fastest?

North America leads with USD 273.4 million of digital PCR revenue in 2025, or 41.3%, on biopharma QC and oncology labs. Asia Pacific grows fastest at 10.45% a year, from USD 154.9 million to USD 418.5 million, because domestic Chinese systems and hospital tenders widen access.

North America reaches USD 535.3 million by 2035 at 6.95% a year; its 6,450 active systems earn about USD 42,400 each. Europe holds USD 189.3 million and grows 6.55% to USD 357.0 million, slowed by academic budgets but supported by cell therapy plants in Germany, France and the UK. Asia Pacific owns 4,910 systems, 27.8% of the fleet, but only 23.4% of revenue, since domestic instruments and reagents sell at lower prices. Latin America is worth USD 25.8 million and grows 8.15%, led by Brazil’s oncology centres. The wildcard is the Middle East and Africa at USD 18.5 million: a small base growing 9.10% that could jump if national genomics programmes standardise on digital PCR for newborn or oncology screening. Lab automation spending drives the same regional order, as our Clinical Lab Automation Market report shows.

Which regulation decides how fast clinical digital PCR assays reach patients?

Two rule changes set the clinical pace for digital PCR between 2025 and 2029. The EU In Vitro Diagnostic Regulation (IVDR) sets certification deadlines of 31 December 2027, 2028 and 2029, while the US FDA has dropped its rule on laboratory-developed tests (LDTs).

Regulation (EU) 2024/1860, published on 9 July 2024, gives legacy class D devices until 31 December 2027, class C until 31 December 2028 and class B and sterile class A until 31 December 2029. Most oncology companion digital PCR kits are class C, so European labs face a 2028 cliff for kits without a notified-body certificate. Europe waits on certificates. Douglas Insights expects about 0.4% of 2028 European digital PCR revenue to shift from lab-built assays to certified kits as a result.

In the US, a federal court vacated the FDA LDT rule on 31 March 2025, and the FDA removed the rule text in a notice published on 19 September 2025, per the Federal Register filing. Reference labs can therefore keep running in-house digital PCR assays on research-use systems without premarket review, which keeps US consumable volumes high but slows sales of FDA-cleared kits such as those for the QXDx system.

How many digital PCR systems will be running by 2035?

34,057 active digital PCR systems will be running by 2035 in our base case, nearly double the 17,640 of 2025, with revenue per system rising to USD 41,445 as clinical kits gain share.

Gross placements must run near 3,900 a year by the early 2030s to deliver that fleet, after retiring the first-generation QX100 and Naica units; Stilla’s Naica line is already end-of-life, per Bio-Rad’s transition notes. Consumables and reagents rise from USD 408.4 million in 2025 to about USD 870.9 million by 2035 at a constant 61.7% mix.

How wide is the digital PCR range for 2035 if funding or MRD adoption moves?

The 2035 digital PCR value runs from USD 1.13 billion in the slower case to USD 1.72 billion in the faster case, around a base of USD 1.41 billion. Volume growth is the swing factor. Price barely moves.

The slower case applies all three headwinds in full: flat academic budgets through 2030, NGS winning MRD reimbursement and IVDR delaying European kit launches. The faster case assumes digital PCR becomes the release assay of record for most viral-vector lots and that QX Continuum-class pricing pulls qPCR users across. One extra point of fleet growth adds about USD 138.0 million to the 2035 figure. Outside forecasts we read put annual growth at 8.15% to 9.4%; our 7.87% is lower because it books the 2025 academic slowdown seen in Bio-Rad’s results and the Stilla consolidation, which removed one price competitor from 7 July 2025.

Douglas Exclusive: the digital PCR installed-base atlas

The atlas is a Douglas Insights model that places 17,640 active digital PCR systems by vendor, platform and region. The model is built from 236 inputs: 31 company disclosures and releases, 148 distributor and tender records and 57 country publication tallies.

By vendor, the atlas counts about 9,650 Bio-Rad and Stilla systems, 3,050 active QIAcuity units out of 3,200 placed, 1,500 Absolute Q systems, 550 Digital LightCycler systems, 2,400 Chinese domestic systems and 490 others. The finding: Asia Pacific holds 27.8% of digital PCR systems but earns USD 31,548 per system, 25.6% below North America, so its revenue share lags its fleet share by 4.4 points. Closing that pull-through gap, not new placements, is the biggest revenue lever in the region.

How the model turns 17,640 digital PCR systems into USD 661.9 million?

17,640 active digital PCR systems multiplied by USD 37,520 average annual revenue per system equals USD 661.9 million. The fleet grows 6.8% and revenue per system 1.0% a year, giving 7.87% and USD 1.41 billion by 2035. Every leg is counted.

Douglas Insights counts 46 countries in five reporting regions and uses 236 data points from the atlas plus 4 vendor financial filings. Cross-check one: Bio-Rad’s published USD 600 million absolute quantitation estimate against our 2024 value of USD 613.6 million, a 2.3% gap. Cross-check two: QIAGEN’s 3,200 cumulative placements against our 3,050 active units, implying 4.7% retirement. Cross-check three: instrument revenue of USD 181.4 million divided by 2,240 placements gives USD 81,000, inside our USD 45,000 to USD 160,000 bands. Lab infrastructure links appear in our Laboratory Grade Water Market study, which uses the same lab census.

Sources

1. Bio-Rad Laboratories Bio-Rad expands Droplet Digital PCR offering through strategic acquisition and platform rollout (2025)
2. Bio-Rad Laboratories Bio-Rad digital PCR investor presentation (2025)
3. Bio-Rad Laboratories Bio-Rad fourth-quarter and full-year 2025 results (2026)
4. QIAGEN N.V., SEC EDGAR QIAGEN full-year 2025 results (Form 6-K) (2026)
5. QIAGEN N.V., SEC EDGAR QIAGEN third-quarter 2025 report (Form 6-K) (2025)
6. Roche Roche launches a digital PCR system (2022)
7. Thermo Fisher Scientific Thermo Fisher Scientific adds digital PCR to genetic analysis capabilities (2021)
8. EUR-Lex, Publications Office of the EU Regulation (EU) 2024/1860 amending IVDR transitional provisions (2024)
9. Federal Register, US FDA Medical devices; laboratory developed tests (rule reversal) (2025)